Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.84−0.16 (-2.29%)
Close on Nov 13, 2026Market cap $733.42MP/E –Yield –
Solid Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Solid Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$220.08M. For fiscal 2025 it was -$177.57M. The highest annual figure on record is -$69.29M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$177.57M | – |
| FY2024 | Dec 31, 2024 | -$127.27M | – |
| FY2023 | Dec 31, 2023 | -$101.67M | – |
| FY2022 | Dec 31, 2022 | -$104.04M | – |
| FY2021 | Dec 31, 2021 | -$69.29M | – |
| FY2020 | Dec 31, 2020 | -$84.48M | – |
| FY2019 | Dec 31, 2019 | -$116.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$57.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$56.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$56.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$47.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.54M | – |
See a number that looks wrong?